adobe stock photos - Sundry Photography RocheSwiss Roche builds its own AI factory with NVIDIA – with Genentech in CaliforniaThe Basel-based pharmaceutical group Roche is pressing ahead with its digital strategy and setting new benchmarks for the industry. Together with NVIDIA, the company is building an “AI factory” that … more ➔
FundraisingMestag Therapeutics raises $40M and adds two senior biotech executives as lead cancer program nears the clinicUK biotech Mestag Therapeutics has raised $40 million and appointed veteran drug developers Lindsey Rolfe as chief medical officer and Pascal Merchiers as chief development officer, as the company prepares … more ➔
adobe stock photos - deemerwhaIntracellular targetingDelivering drugs into cells: Seed funding for German iDEL and its ‘wonder shuttle’The new Dortmund-based biotech iDEL Therapeutics has launched with a €9 million seed round to develop a new class of cancer therapies. The financing was led by BiomedVC, with participation from NRW.Venture, … more ➔
AITernary Therapeutics lands €4.1M seed round to push AI-designed molecular glues into inflammatory diseaseLondon-based Ternary Therapeutics has raised a €4.1 million seed round to expand its platform for designing molecular glue drugs, with Paris-based VC daphni leading the financing alongside Pace Ventures, … more ➔
AIOwkin spins out AI diagnostics startup Waiv with $33M financingFrench AI biotech Owkin has spun out its diagnostics division as a new company, Waiv, raising $33 million in financing led by OTB Ventures and Alpha Intelligence Capital to scale AI-powered precision … more ➔
Valanx BiotechAntibody drug conjugatesVienna’s VALANX secures €3 million to push preclinical ADC programme in breast cancerVALANX Biotech has raised €3 million in a Series A funding round to advance an antibody-drug conjugate (ADC) targeting LIV-1 for triple-negative breast cancer. The developments are currently still … more ➔
M&AEnodia strikes up to $127m deal for Kezar’s preclinical protein degradation assetsParis-based Enodia Therapeutics announced the acquisition of preclinical assets from San Francisco-based Kezar Life Sciences’ pipeline. Both companies are developers of small molecules that target … more ➔
Evotec SEEvotecHamburg CRO Evotec to cut costs further and reduce workforce by 800Cost-cutting measures sometimes arrive wrapped in reassuring language. “Horizon” is the name Evotec SE has given to the next stage of its restructuring programme, which will affect additional sites … more ➔
Unsplash+Drug developmentIpsen withdraws cancer drug following safety concernsIpsen has announced the immediate withdrawal of its cancer drug Tazverik across all indications after serious safety issues emerged in an ongoing Phase III trial. more ➔
Marcus Krauss - stock.adobe.com BioNTechA new departure: BioNTech’s founders step aside – Sahin and Türeci in new ventureThe Mainz-based biotech company BioNTech is facing a historic leadership change as the minds behind the COVID-19 vaccine prepare for a fresh start. Uğur Şahin and Özlem Türeci plan to focus entirely … more ➔
adobe stock photos - Sundry Photography 
adobe stock photos - deemerwha
Valanx Biotech
Evotec SE
Unsplash+
Marcus Krauss - stock.adobe.com